A similar re-induction of MDA expression was achieved by MAPK pathway inhibition – with a MEK inhibitor in all cell lines or with a BRAFV600E/K inhibitor in BRAFMut cell lines – suggesting that RSK serves as a downstream mediator of MAPK pathway-controlled melanoma cell dedifferentiation (Suppl. This evidence concerns the gene RPS6KA3 and melanoma.